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                                     INTRODUCTION 
Coronary artery disease, the number one killer in the world, is a 
disease of the heart where the coronary arteries are either partially 
occluded resulting in myocardial ischemia, or totally occluded resulting 
in myocardial infarction (MI). MI could be a minor event, perhaps not 
even recognized, or it may be a major attack with results varying from 
acute pain, hemodynamic deterioration to sudden death. The early 
detection of an infarction greatly improves the patients’ chances of 
survival and return to health and is therefore very important. 
The real incidence of acute myocardial infarction is difficult to 
judge because of varied reporting pattern. Moreover increased incidence 
of diabetes and obesity, stemming from global shift to western diet and 
lifestyle will increase consequent coronary artery disease in the near 
future.  
Death due to silent ischaemia is common especially in diabetics 
and elderly and it’s the common cause of sudden death outside the 
hospital 
  The mortality rate of patients with presumed myocardial infarction 
or acute coronary syndrome in the first month is ~50% and of these 
deaths about half occur within the first 2 hrs. For the first six months after 
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infarction, the risk of developing  sudden death is still high, but this risk 
falls after this period. Anterior infarction carries a grave prognosis if 
accompanied by conduction disturbances. All the major complications 
worsen the prognosis. Age above 70 years, hypertension, diabetes and 
heavy cigarette smoking worsen the outlook further.   
Patients  requiring cardiopulmonary resuscitation during the course 
of the illness run a higher risk of fatal arrhythmias in the first few years 
after discharge from hospital. Evidence is that atleast a small proportion 
of cardiac myocytes compensate to make up for the lost cells, on long 
term follow up.  The high initial mortality of MI has decreased with the 
advent of coronary care unit, fibrinolytic therapy and catheter based 
reperfusion.  Although primary percutaneous coronary intervention (PCI) 
has been shown to decrease mortality, a significant number of patients 
with acute MI are not eligible for this as they cannot reach hospitals 
within the required time window.  As the elderly constitute an increasing 
proportion of those presenting with acute MI having high mortality, but is 
not eligible for fibrinolytic therapy, MI may continue to remain the 
leading cause of death over the next several decades. 
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Myocardial infarction may be revealed by any of the following - 
clinical symptoms and signs, biochemical markers, imaging or 
pathological characteristics, but the most important initial clinical test for 
diagnosis of MI remains electrocardiography. The relative ease of use, 
low cost and particularly the non-invasiveness and speed makes it an 
excellent tool for a patient with suspicion of MI. 
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REVIEW OF LITERATURE 
Currently, India is going through a phase of epidemiological 
transition, where there is a shift in the cause of mortality from 
communicable diseases to non-communicable diseases, particularly 
Cardiovascular disease (CVD). It affects Indian population earlier and 
denies many youngsters of their  most productive  life years. Researchers 
in India and international agencies like World Health Organization  , 
found a steady increase in the burden of cardiovascular disease over the 
past 15 years. 
           The disease is more prevalent in the urban population and has a 
clear variation in prevalence from rural to semi-urban population. In the 
Indian scenario, it has been predicted that by the year 2020, there will be 
an increase by almost 75% in the cardiovascular disease burden
3
.  
 
Urban India 
1960 1% 
1995 8 – 10% 
 
Rural India 
1974 2% 
1995 4% 
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In the last 5 decades in urban India, coronary artery disease (CAD) 
has increased more than 6 fold and the current prevalence rate of CAD is 
10%  in the 35 to 65 years age group.   The prevalence has almost 
doubled in the rural areas too over the few decades .  CVD has thus begun 
to outrank infectious diseases in causing death. In India the peak period 
of occurrence of MI is seen to be between 51-60 yrs i.e. it appears a 
decade earlier in India as compared to the developed countries. 
 
ANATOMY OF CORONARY 
ARTERIES
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Coronary arteries arise from coronary sinuses at the base of the aorta. 
- LCA( Left main Coronary Artery) divides into 
-  Left Anterior Descending (LAD) - gives septal and diagonal 
branches 
- Circumflex Artery (LCX)- gives marginal branches and  
  occasionally the posterior descending artery 
- RCA (Right Coronary Artery) gives off 
– Atrial branches,conus branch,marginal branches  
– SA nodal, AV nodal and septal branches  
– Posterior descending branch  
CORONARY CIRCULATION 
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Coronary blood flow in humans during rest is about 225-250 
ml/minute, which is about 5% of cardiac output. At rest the heart extracts 
60-70% of oxygen from each unit of blood delivered to it -other tissues 
extract only 25% of O2-as myocardium has more mitochondria, 
occupying upto 40% of the myocyte.  When more oxygen is needed as in 
exercise, O2 delivery can be increased only by increasing the blood flow. 
During systole when the heart contracts it compresses the coronary 
arteries, therefore blood flow to the left ventricle is less during systole 
and more during diastole. The subendocardial portion of left ventricle is 
perfused only during diastole. Coronary blood flow to the right ventricle 
is not much affected during systole as the pressure difference between 
aorta and right ventricle is greater during systole than in diastole. Hence 
more  blood flow occurs to the right ventricle during systole. 
CORONARY BLOOD FLOW  
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As we know blood flow to subendocardial region of left ventricle is 
nil during systole and is therefore prone to ischemic damage and is the 
most common site of myocardial infarction. Heart uses primarily free 
fatty acids and to a lesser extent glucose and lactate for metabolism. In 
ischemic / anaerobic conditions it derives energy from anaerobic 
glycolysis forming lactic acid, one of the causes of cardiac pain. 
FACTORS AFFECTING BLOOD FLOW TO CORONARY ARTERIES 
     - Aortic pressure 
     - Chemical factors 
     - Neural factors 
Coronary blood flow shows considerable autoregulation. 
Chemical factors affecting Coronary blood flow 
 Chemical factors causing Coronary vasodilatation (Increased 
coronary blood flow) 
 Lack of oxygen 
 Increased local concentration of Co2 
 Increased local pH 
 Increased local concentration of K+  
 Increased local concentration of lactate, prostaglandins, 
adenine nucleotides. 
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 Adenosine formed from ATP during cardiac metabolic 
activity 
 Neural factors affecting Coronary Blood Flow 
 Effect of Sympathetic stimulation 
 Effect of Parasympathetic stimulation 
 Sympathetic stimulation: Coronary arteries have Alpha 
Adrenergic receptors that cause vasoconstriction and Beta 
Adrenergic receptors  that cause vasodilatation. 
 Effect of Parasympathetic stimulation : Vagal stimulation 
causes coronary vasodilatation. 
 
SPECTRUM OF CORONARY ARTERY DISEASE: 
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Patients who have CAD may present with stable angina or ACS 
(Acute Coronary Syndrome). Acute coronary syndrome includes UA 
(Unstable Angina) and MI with or without ST-segment elevation . 
Unstable angina is characterised by increase in the duration, severity and 
frequency of chest pain, with or without ST depression or T wave 
inversion in ECG.    The clinical manifestations of non ST elevation MI is 
similar to Unstable angina and its differentiated from the later by the 
presence of cardiac enzymes. 
MYOCARDIAL INFARCTION                   
DEFINITION  
 
ECG evidence of ST-segment elevation of more than 1mm in two 
or more  contiguous limb leads (from aVL to III, including  aVR), 
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  ST-segment elevation  more than 1 mm  in precordial leads  
V4 through V6,ST-segment elevation more than 2 mm in 
precordial leads V1 through V3, or New left bundle-branch block. 
For diagnosing the occurrence of MI in patients with chest pain and 
LBBB, Sgarbossa scoring system was devised that takes into account  
1.  ST-segment elevation ≥ 1 mm in a lead with  positive QRS complex (5 
points) 
2.  ST-segment depression ≥ 1 mm in V1, V2, or V3 (3 points) 
3.  ST-segment elevation ≥ 5 mm in a lead with  negative QRS complex (2 
points) 
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Scores > 3 has 90% specificity for MI. Criteria  1 is more specific  
of a ST elevation MI than criteria 3, and  as  more criteria is fulfilled, the 
more likely that the patient is suffering from MI. 
  Positive tests for cardiac enzymes troponin and creatinine kinase 
isoenzyme MB are helpful, but not essential.
1
  Secondary  ST wave 
changes  in the leads corresponding to the opposite side of the heart) 
make the diagnosis  of STEMI more specific. 
CLASSIFICATION OF MI 
 
 
I .CONVENTIONAL RISK FACTORS 
II.UNCONVENTIONAL RISK FACTORS 
 The conventional risk factors can be further divided into non 
modifiable risk factors & potentially modifiable risk factors. 
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THE NON MODIFIABLE RISK FACTORS 
1. Increasing age 
84 % of people who die of coronary artery disease are 65 years   or 
older. In old age the chance of occurrence of Myocardial infarction   
increases due to   the deposition of atherosclerotic plaques   in the blood 
vessels. Age also increases the morbidity of the disease persay. 
 2.    Male sex ( gender) 
Men are at an increased risk for the development of Myocardial 
Infarction than women. Oestrogen seems to have a protective role against 
M.I. After menopause the risk is almost equal in men and women.   
3.     Heredity including Race 
  Incidence of M.I is higher in South Asian population.  Family 
history of CAD especially paternal history of Myocardial infarction is 
associated with increased occurrence of premature myocardial Infarction 
in young men and its probably due to accelerated atherosclerotic process.  
THE POTENTIALLY MODIFIABLE   RISK FACTORS  
1. Tobacco Smoking  
It contributes to one quarter of CAD deaths in young men ,and lot 
of awareness has been created regarding smoking. Tobacco smoking   
increases the risk of M.I.  by   2-4 times and cigarette smokers have twice 
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the risk of sudden cardiac  death than non smokers. It  significantly 
contributes to the atherosclerotic process and also synergises  with other 
risk  factors  to greatly  increase the risk of coronary  artery disease.  
Exposure to other peoples’ smoke ie. passive smoking also increases the   
risk of   heart disease   in non-smokers. 
2.   Dietary Factors  
There exists a triangular relationship   between the   habitual   diet, 
blood cholesterol - lipoprotein levels and coronary artery disease.  
Increased intake of food containing saturated and mono unsaturated 
(trans) fatty acids and decreased consumption of poly unsaturated   fatty    
acids increases the risk for myocardial infarction.   
 The Seven Countries Study showed that serum cholesterol is an 
important risk factor for the   incidence of CAD at levels of 220 mg/dl or 
more. The level of low- density lipoprotein (LDL) is directly associated   
with CAD. Very low density lipoprotein (VLDL) is shown to   be 
associated with premature atherosclerosis. High Density lipoprotein 
(HDL) is protective against the occurrence of CAD.  HDL levels   should   
be more than 30 mg/dl to exert a protective effect and LDL levels should 
ideally be less than 200 mg/dl. 
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Increased salt consumption is associated with the development of 
hypertension which in turn increases the risk of M.I.   
3. Hypertension  
Hypertension  fastens the atherosclerotic process and  increases the 
risk of  myocardial infarction.  According to the current data, 30 % of the 
patients with hypertension develop myocardial infarction.  Systolic  blood 
pressure  predicts the occurrence of CAD better than diastolic blood 
pressure. 
4.   Diabetes Mellitus 
  Today diabetes is considered as a CAD equivalent.  The risk of   
CAD is 2-4 times higher in diabetics than in non- diabetics. CAD 
accounts for 30-50 % of deaths in diabetics above the age of 40 years in 
industrialized countries.  They suffer twice the morbidity and mortality   
when compared to non – diabetics.   
5.  Obesity and Physical Inactivity 
In the current era, obesity is high and its becoming one of the 
major risk factors in the occurrence of MI. Central obesity (intra 
abdominal fat deposition) is an important determinant for the 
development of insulin resistance and metabolic syndrome  
(hyperinsulinemia, dyslipidemia,  glucose  intolerance  and hypertension).  
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This again links obesity to CAD. Physical inactivity and   sedentary   
occupation leads to decreased energy expenditure and is the most   
important etiology of obesity. Exercise plays a major role in retarding the 
development of obesity.  
6. Metabolic Syndrome  
Metabolic Syndrome worsens CAD.  Criteria includes: 
Increased waist circumference (Asian Males > 90 cm,   Females 
 > 80 cm) plus at least 2 of the following:-  
1) Triglyceride  ≥ 150 mg/ dl  
2)  HDL – Cholesterol < 40 mg/dl (men); 50 mg / dl (women) or on 
HDL – cholesterol treatment  
3) Systolic BP ≥ 130 and/or Diastolic BP ≥ 85 mm Hg.   
4)  Fasting Blood glucose ≥ 100 mg / dl or Impaired Glucose 
Tolerance  Test or known diabetic. 
II. Unconventional / Emerging Risk Factors  
1.   Homocysteine :  
Increased levels of homocysteine causes cardiovascular disease. 
Diets rich in dietary fibre and low in monounsaturated fatty acids 
decrease the level of homocysteine. 
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2)  Malnutrition   
Type B malnutrition occurs due to high calorie and low 
micronutrient intake and can cause obesity leading to an increased  risk of 
CAD.   
3) Depression  
Depressive patients are more likely to develop CAD when 
compared to non depressive patients. Treatment of depression   improves 
the outlook of patients with CAD.  
4) Cocaine  
 According to a study done by the National Heart Lung and Blood   
Institute, the American Heart Association reports that the risk of 
myocardial infarction was elevated by 23.7 times in 60 minutes after 
cocaine use.  Cocaine causes   spastic contraction of the coronary   blood 
vessels   that leads to myocardial ischemia and increases the rise of M.I.   
CAUSES OF MI 
Atherosclerosis of the coronary arteries is the most important and 
most common cause of MI. However numerous pathological processes 
other than atherosclerosis contribute to MI. For example, coronary artery 
occlusions can result in embolization to the coronary arteries. Emboli 
most commonly lodge in the left anterior descending artery, more so in 
 24 
the epicardial and transmural branches. The  etiology of coronary 
embolism are numerous like infective endocarditis and nonbacterial 
thrombotic endocarditis, mural thrombi, prosthetic valves, neoplasms, air 
that is introduced at the time of cardiac surgery and calcium deposits 
from manipulation of calcified valves at operation. In situ thrombosis of 
coronary arteries  can occur secondary to chest wall trauma. 
A variety of inflammatory processes can be responsible for 
coronary artery abnormalities, some of which mimic atherosclerotic 
disease and may predispose to true atherosclerosis. Epidemiological 
evidence suggests that viral infections, particularly with coxsackie B, 
may be an uncommon cause of AMI. Viral infections precede AMI 
occasionally in young persons who are later shown to have normal 
coronary arteries. 
Syphilitic aortitis may produce marked narrowing or occlusion of 
one or both coronary ostia, whereas Takayasu’s arteritis may result in 
obstruction of the coronary arteries. Necrotising arteritis, polyarteritis 
nodosa, mucocutaneous lymph node syndrome ( Kawasaki disease ), 
systemic lupus erythematosus and giant cell arteritis can cause coronary 
occlusion. Therapeutic levels of mediastinal radiation can cause 
thickening and hyalinization in the walls of coronary arteries, with 
subsequent infarction. AMI may also be the result of coronary arterial 
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involvement in amyloidosis, hurler syndrome, pseudoxanthoma elasticum 
and homocystinuria. 
       As cocaine abuse has become more common, reports of AMI 
following the use of cocaine has appeared with increasing frequency. 
Cocaine may cause AMI in patients with normal coronary arteries, pre-
existing MI, documented coronary artery disease or coronary artery 
spasm.   
Pathophysiology of ST ELEVATION MI 
8
Myocardial infarction (MI) is due to obstruction to coronary blood 
flow, with atleast 75 % of the lumen being blocked by thrombus. The 
process of atheroma formation involves the intima of large and medium 
arteries. Progesses overtime, before manifesting itself as an ACS.  The 
whole pathophysiology of MI involves a complex interplay between the 
endothelium, inflammatory mediators and coagulability of blood. After 
the plaque ruptures, the sub endothelial matrix is exposed to the 
circulating blood; this exposure leads to platelet adhesion followed by 
platelet activation and aggregation and the subsequent formation of 
thrombus. Two types of thrombi can form : a platelet rich clot( white clot) 
that forms at areas of high shear stress and partially occludes the artery, or 
fibrin rich clot ( a red clot ) that is the result of an activated coagulation 
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cascade and decreased flow in the artery. Red clots are frequently 
superimposed on white clots, and cause total occlusion resulting in 
STEMI ; when occlusion is sub total , UA/ NSTEMI are usually the 
result
9
. 
          The high risk vulnerable plaques are composed of a lipid rich 
centre , thin fibrous caps, a relative  high number of macrophages and T 
lymphocytes, a relative few  smooth muscle cells,  increased expression 
of matrix metalloproteinases ,eccentric outward remodelling and 
increased neovascularity  of the plaque and intraplaque haemorrhage. 
Inflammation ,an important determinant of the vulnerability of plaques , 
is related to an increase in the activity of macrophages at the site of 
plaque. Seventy percent of lesions on coronary angiography that cause 
ACS are less than 50% stenosis of arterial diameter. So most ACS 
episodes are due to rupture of non obstructive plaques. The plaque 
usually ruptures at shoulder point. 
Several complications may develop like haemorrhage into the 
atheroma, ulceration of the intimal surface, embolization of the 
atheromatous plaque, thrombosis starting at the narrowed portion of the 
arteries, and calcification. Progressive occlusion of the lumen of the 
coronary arteries may remain totally asymptomatic till the circulation is 
considerably diminished. In general, the development of complications 
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gives rise to one of the clinically detectable syndromes. Once a coronary 
artery is occluded and the myocardium rendered ischaemic, gross changes 
are noticeable by six hours. The infarct appears pale, blue and edematous. 
Early histological features are interstitial edema, neutrophilic infiltration 
and clumping of muscle cells. Granulation tissue appears by the tenth 
day. The infarct is converted into a scar by the sixth week. An infarct may 
involve the total thickness of the ventricular myocardium (transmural 
infarcts) or may be confined to the sub endocardial region depending on 
the vessel occluded. 
Further changes may develop over the area of initial infarction. 
These are 1. Extension of infarct leading to further loss of ventricular 
function. 
 2. Involvement of conducting tissues leading to disruption of  
impulse conduction . 
 3. Rupture of the infarct resulting in hemopericardium. 
 4. Inflammation of the overlying pericardium giving rise to 
pericarditis and 
 5. Formation of ventricular aneurysm. The ischaemic myocardium 
is electrically unstable and this acts as a focus for ectopic impulses, which 
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give rise to several arrhythmias in the immediate post infarcation period. 
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•  ISCHAEMIC PRE CONDITIONING AND COLLATERAL 
FLOW 
23
In addition to the duration of ischemia, there are other factors that 
affect the consequences of coronary occlusion. If the myocardium is 
subjected to repetitive short ischemic episodes, it increases its protection 
against subsequent prolonged ischemic episodes. It has been shown to 
reduce the level of ST-segment deviation and decrease MI size.
15 
The 
mechanisms for the preconditioning are complicated and not fully 
elucidated. They involve a much lower consumption of ATP, delayed 
development of acidosis and slower accumulation of lactate in 
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preconditioned compared to the non preconditioned myocardium. 
13
This 
suggests that preconditioned myocardium has a reduced energy 
requirement and consequently a delayed myocyte death when the blood 
ﬂow is disrupted .The concept of ischemic preconditioning in humans has 
been supported by many clinical trials. 
• Myocardial stunning14.  
The normalization of cardiac function can be preceded by a  relatively 
brief  period of  decrease in cardiac function (hypokinesia) caused by 
myocardial stunning.
 Stunned myocardium has been deﬁned by 
Braunwald and Kloner as "prolonged, postischemic dysfunction of viable 
tissue salvaged by reperfusion". Thus, myocardial stunning
14
 may occur 
even without MI. The time and degree of recovery of cardiac function in 
stunned myocardium depends on the duration and severity of ischemia 
and on the adequacy  blood ﬂow restoration. 
• Myocardial hibernation16 
A reduction in myocardial function can also be caused by a 
persistent decrease in blood ﬂow due to a tight coronary stenosis. The 
blood supply to the myocardium in the area distal to the stenosis is very 
low for the myocardium to contract properly but is sufficient for it to 
remain viable. This phenomenon is called myocardial hibernation and has 
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been described as "a state of persistently impaired myocardial and LV 
function at rest due to reduced coronary blood ﬂow which can be partially 
or completely restored to normal if the myocardial oxygen 
supply/demand relationship is favorably altered, either by improving 
blood ﬂow  and/or by decreasing the demand." Thus the hibernating 
myocardium has the ability to recover its function in contrast to  
myocardium  that is infarcted. 
• 13Myocardial remodelling.  
In situations where the MI is large enough to cause permanent 
partial loss of cardiac function, there is a need to compensate for this 
functional loss.
14 
The changed loading conditions stimulate myocardial 
remodelling, which can alter the topography of both the infarcted and 
viable myocardium. An early alteration of the infarcted myocardium, 
especially in transmural MI, is infarct expansion. Infarct expansion is 
deﬁned as "acute dilatation and thinning of the area of infarction that 
cannot be explained by additional myocardial necrosis."
25
 Depending on 
the extent of MI, the remodelling process varies from well adapted 
compensatory hypertrophy called as positive remodelling to pronounced 
wall thinning and aneurysm formation referred to as negative 
remodelling. As the MI size increases, the risk of ventricular dilatation 
and heart failure subsequently increases. 
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CLINICAL  PRESENTATION 
 
MI is characterised by the occurrence of severe retrosternal pain 
with the characteristic radiation to the jaw, shoulder and back. The pain is 
usually severe and excruciating and is usually described as compressive 
pain not relieved with rest or sublingual nitroglycerine and its associated 
with dyspnoea, excessive sweating, vomiting, palpitations. It is important 
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to know the time of onset of chest pain, as its important in determining 
the means of reperfusion. ST elevation MI may have atypical 
presentations in women, elderly and post operative patients as well as 
those with diabetes and chronic kidney disease.   Some patients may 
present with anginal equivalents like dyspnoea, syncope, palpitations , 
unexplained hypotension or congestive cardiac failure.  If the patient has 
a history of previous cardiac catherisation or revascularisation its 
important to obtain these records, as these provide valuable  information 
with respect to PCI  planning. MI  follows the circardian rhythm in that a 
good number of cases occur in the early hours of morning. 
SIGNS : 
   Physical findings should be directed towards identifying 
hemodynamic instability, pulmonary congestion, mechanical 
complications of MI, and other causes of acute chest discomfort.  In 20% 
of cases the symptoms may be trivial and physical examination may be 
unrewarding, however in a few the findings are characteristic. The 
identification of a new pan systolic murmur may suggest the presence of 
ischaemic MR ( mitral regurgitation), or   VSR (ventricular septal 
rupture). A neurological assessment should be done to detect motor 
deficits and vascular examination like peripheral pulses and bruits should 
be looked for  . Cardiogenic shock due to right ventricular myocardial 
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infarction or extensive anterior wall MI should be be clinically suspected 
in  the presence of  feeble pulses, low or unrecordable BP  and  a raised 
jugular venous pressure. While RV MI may be seen in isolation, it may be 
more commonly associated with inferior/ posterior MI  . Bilateral  arm 
BPs should be obtained to assess for the presence of aortic dissection.  
On the second or third day pericardial friction rub may be heard or 
a pericardial effusion may develop. If complication develop these will be 
clinically evident. 
 
INVESTIGATIONS  
ENZYMES: Several enzymes and other components of cardiac 
muscle are liberated into the circulation from injured and necrotic 
myocardium. Their presence above diagnostic levels, their peak levels in 
plasma and the pattern of their rise and fall, have been established. 
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CPK MB: it’s a high energy transfer cytoplasmic protein which 
originates from cardiac and skeletal muscle. Its detectable within 2- 3 
hours, 94% sensitivity at 8 hours and < 50% at 2 hours. It returns to 
normal in 24 – 48 hours. Advantage is that it can detect early reinfarction. 
Low sensitivity for detection of very early (<6 hours) MI small MI ; false 
positive with skeletal muscle trauma, CPR, Cardioversion and cardiac 
surgery. 
MYOGLOBIN:    
Its an O2 binding haem protein that is rapidly released with 
myocyte injury.  It originates from cardiac and skeletal muscle, detectable  
within 1.5 – 2 hours and  returns to normal in 8 to 12 hours. It is marker 
to detect very early MI. 
CARDIAC TROPONINS:  
These are regulatory proteins for calcium dependent interactions 
between actin and myosin. They originate from the cardiac muscle, 
released within 3–4 hours, return to normal within 10–14 days. Troponins 
are sensitive and specific than CPK –MB. It’s the best marker for MI with 
skeletal muscle injury, small MI, or late MI (> 2 -3 days). Low sensitivity 
for detection of early MI or late reinfarcation. 
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SUBSET TOTAL CPK CK -MB MYOGLOBIN CARDIAC 
TROPONIN 
MI < 4 HOURS _ _ + _ 
MI 4 – 12 HOURS + + + + 
MI > 2 TO 10 
DAYS 
_ _ _ ≥ 
EARLY 
REINFARCTION 
+ + ≥ _ 
SMALL MI _ _ _ + 
MI AFTER 
OPERATION  OR 
TRAUMA 
_ ≥ _ + 
+ USEFUL, ≥ SOME VALUE, - NOT USEFUL. 
 ECG IN MI : 
• 12While coronary angiography remains the “gold standard” for 
identifying the infarct related artery, the ECG remains the gold 
standard for identifying the presence and location of acute myocardial 
ischaemia. 
 
A possible consequence of myocardial ischemia is 
myocyte death. ECG abnormalities are not due to injury currents, but 
rather due to the established MI.  MI affects the local activation 
sources of the myocardium, seen as deviation of the QRS waveforms 
away from an electrode overlaying the infarcted area. It might also 
 37 
cause persistent alteration of myocardial repolarization, resulting in T 
wave alterations. The QRS complex is altered to a considerable  
degree in variable leads depending on the size, location and 
morphology of the MI.  The extent of MI is dependent on which vessel 
is occluded.
 
The myocardial activation (depolarization) vector is a 
result of all parts of the myocardium that are depolarized at a given 
time point. The result of the time resolved propagation of the 
depolarization vector during a single cardiac cycle is what causes the 
deﬂections of the QRS complex seen in different leads. Regions of MI 
will inﬂuence the normal depolarization vector according to the size, 
location and morphology of the MI. If the initial depolarization forces 
are directed away from an overlying lead, the initial QRS deﬂection in 
that lead will be negative, resulting in a Q wave. Thus, presence of Q 
waves can be a sign of MI. 
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ECHOCARDIOGRAPHY :  
This may reveal wall motion abnormalities, chamber size, 
myocardial fibrosis, edema, thinning of ventricular wall, hypertrophy, and 
others. It can help to evaluate cardiac hemodynamics by using colour 
Doppler. It may also be used to identify the progress from ischaemia to 
infarction. 
NUCLEAR IMAGING:  
Radionuclide imaging, angiography, perfusion imaging, infarct 
avid scintigraphy and positron emission tomography area all in the use to 
study the nature of the myocardial lesion, its viability and prognosis. 
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CORONARY ANGIOGRAPHY : 
Angiography is the key in diagnosing the extent, location, and 
severity of lesions and in planning revascularisation (PCI or CABG). 
More than 80% of patients with UA/ NSTEMI show significant coronary 
lesions on coronary angiography. 
ESTIMATION OF INFARCT SIZE
12 
 Its essential to estimate the size of infarct as it has got a significant 
value in terms of prognosis and many clinical methods have been 
evaluated to determine their ability to estimate in the size of 
myocardial infarcts. Early estimation of infarct size is necessary for 
predicting the severity of infarction and planning the rehabilitation 
program. Methods of estimating infarct size include 
• CPK 
• ECG 
• CEMRI 
• A12new method to estimate infarct size is using dual single photon 
emission computed tomography (dual SPECT) with 201 T1 and 
technetium-99m pyrophosphate. 
For determining the presence and location of infarcts however, the 12-
lead ECG remains the standard because it is universally available, 
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noninvasive, inexpensive and easily repeatable. It is important to know 
the extent to which ECG could be used for estimating infarct size. 
Studies of the sequence of activation in QRS complexes in both 
canine and human hearts have provided the basis for computer 
simulations that suggest an orderly and predictable sequence of changes 
that occurs in QRS associated with infarcts of various locations and sizes. 
Through various pilot studies in patients with localized wall motion 
abnormalities seen by ventriculography, Selvester et al. refined the results 
of these computer simulations to produce both qualitative and 
quantitative criteria for determining infarct size. 
SELVESTER QRS SCORING SYSTEM 
The Selvester QRS Score which is an electrocardiographic (ECG) 
method for estimating MI size, was first proposed by Selvester et al and  
it was later modified by Wagner and Palmeri. The Selvester QRS score, 
which was  first  put forth in  the year 1972, converts the  changes in 
cardiac electrical activity into information  that help us in determining the 
infarct size and location. 
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•  The infarct size estimated by this scoring system has shown to have  a 
reliable and good correlation with the myocardial infarct size measured 
at autopsy.  Various studies have proved that the   QRS score estimated 
in the patients post MI provided valuable information regarding 
prognosis. Higher QRS score is indicative of increased occurrence of 
ventricular tachyarrhymthias and the need for increased defibrillatory 
shocks and decreased response to cardiac resynchronisation therapy. 
The size of a myocardial infarct is estimated electro cardiographically 
using this QRS scoring system to accumulate a point score. 
12
Ten ECG 
leads (1,II, aVL, aVF, V1-V6) are weighted according to their ability to 
reflect infarct size as established by Selvester etal. Certain criteria in the 
original scoring system are not evaluated. Qualitative criteria, such as 
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slurs or notches, are not considered because of the difficulty of 
establishing definitions that can be applied uniformly to clinically 
performed ECGs from a large number of patients. 
 
 
 
 
 
 
 
The single-point R/Q criteria in leads V4 and V5 were modified, in 
addition to the single-point R/S criteria to simplify the scoring system.  
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•  
The modified Selvester QRS scoring system achieves an 
acceptable level of specificity when confounding variables such as left or 
right ventricular hypertrophy, left or right bundle branch block, or left 
anterior or posterior fascicular block are excluded. Each criterion 
exhibited at least 95% specificity and the total 29-point scoring system 
achieved 98% specificity when a score of more than 2 points was 
required for identification of infarction. The confounding variables noted 
above will probably diminish the specificity,thus limiting the value of this 
scoring system for identifying and measuring infarct size in some 
patients. 
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However, the specificity must be established. Some of the criteria 
may retain their importance in the presence of other factors that can alter 
the QRS complex. The QRS scoring system also allows acceptable levels 
of both intra and inter observer agreement.Each of the 37 criteria 
achieved 91% or greater intraobserver agreement and 92% or greater 
interobserver agreement. 
QRS SCORING AND EJECTION FRACTION 
  QRS changes resolve owing to healing that occurs in the infarcted 
area, its associated with scar retraction and hypertrophy of the nearby 
myocardium  and it has been established to be indicative of retained LV 
function. It has been validated in many studies that early reperfusion 
strategies acclerate the healing process and recovery of LV dysfunction 
and bring about resolution in QRS changes. 
PROGNOSTIC VALUE OF  QRS  SCORING 
Higher QRS score is associated with higher mortality in patients 
with MI. Patients with a score of 0 had a  survival rate of 95%  at the end 
of one year and  88% survival at the end of  five years; patients with a 
score of ten  or more had survival rates of 81% and 52%, respectively ,at 
one and 5 year intervals. 
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Though the size of the infarct can be reliably predicted  using   
magnetic resonance imaging, single photon emission computed 
tomography or positron emission tomography , ECG asssessment is easy 
to perform,  and non invasive. The most predictive electrocardiographic  
sign of old myocardial infarction  is the presence of pathological Q-
waves, but the  Q-waves however are not  reliable  because it  does not 
represent the involved myocardial segments  and further there is now an 
increasing trend of non Q wave infarctions and in some inferior wall 
infarctions Q waves tend to disappear. Selvester QRS score has shown to 
be superior to various other scoring systems like minnesota score, 
novacode, and cardiac infarction injury score in estimating the infarct size 
.This scoring system has also proven to be useful for predicting recovery 
of  LV function after acute MI,  and also it gives maximum information 
regarding the  prognosis. Thus MODIFIED SELVESTER QRS  scoring  
system can be a very effective clinical tool for physicians. Even Q waves 
as small as 20 msec in some leads and 30msec in other leads of a standard 
ECG are rarely present in normal controls. Both intra- and interobserver 
agreements are acceptable. 
ROLE OF ST SEGMENT RESOLUTION IN MI 
• Rapid ways are required to estimate the effectiveness of reperfusion 
with respect to clinical grounds and also in clinical trials. The ST 
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segment resolution has recently gained lot of importance in this 
perspective. ST segment monitoring  and  resolution  of ST segment as 
a simple means of  predicting reperfusion in patients receiving 
reperfusion therapy for acute ST elevation myocardial infarction, is 
now being used to a large extent in clinical practice and in many 
research studies.  
10
The ST-segment resolution has gone a long way in assessing the 
chances of reperfusion in the absence of coronary angiogram. When 
compared to TIMI flow ST segment resolution is better in predicting the 
outcome of patients undergoing primary angioplasty.  Thus ST-segment 
resolution 60–90 minutes after thrombolysis is an excellent marker of 
successful myocardial reperfusion.   
 The efficacy of thrombolytic agents have been assessed 
using the Thrombolysis in Myocardial Infarction trial flow grade 
classification (TIMI). This classification estimates the coronary blood 
flow in the infarct-related artery after thrombolysis. Various factors 
seem to influence TIMI flow grade after fibrinolysis, these include 
hemodynamics, coronary anatomy, amount of residual thrombus, and  
other cellular factors. 
 47 
 TIMI 0 flow -    No antegrade flow beyond a coronary occlusion 
 TIMI 1 flow -  Faint antegrade coronary flow beyond the occlusion,  
filling  of the coronary bed distal to the occlusion is incomplete. 
 TIMI 2 flow - Delayed or sluggish antegrade flow with complete 
filling    of the territory distal to the occlusion. 
 TIMI 3 flow  -  Normal flow with complete filling of the distal 
coronary bed 
 
 Numerous clinical trials have predicted that early  resolution of ST 
segment  in MI  patients is associated with a high infarct-related artery 
patency, smaller size of the infarct, better left ventricular ejection 
fraction, and lower  death rates at one, six months and at six years. Till 
today,  many   studies have evaluated the prognostic value of ST segment 
resolution as early as 90 minutes and up to 4 hours after fibrinolysis and 
established it to be a reliable  bedside marker of prompt reperfusion  of 
the infarcted artery.
 
ST-segment resolution (STR) is a well-established 
and simple tool for assessing the efficacy of reperfusion therapy in 
myocardial infarction. An incomplete (<50%) STR is a recognized 
marker of failed thrombolysis and a suitable recruitment criterion for 
rescue angioplasty. 
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DIAGNOSIS AND MANAGEMENT OF MI 
 
Risk stratification IN MI 
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Patients of ACS have variable prognosis. At one end of spectrum 
are young patients with new onset angina, no ECG changes, no elevated 
biomarkers and no hemodynamic instability. These patients are managed 
pharmacologically and they should undergo non invasive testing (TMT, 
stress echocardiography) after 10 days of symptom onset. At the other 
end are with history of recurrent / rest angina, fresh ECG changes, 
elevated biomarkers and, haemodynamically unstable patients who need 
early invasive strategy in the form of PCI. 
 The GRACE model  
 Advanced age 
 Killip class 
 Systolic blood pressure 
 ST-segment deviation 
 Cardiac arrest during presentation 
 Serum creatinine level 
 Elevation of initial cardiac biomarkers 
 Heart rate 
 
 It  has the best predictive accuracy for death or MI at 1 year.  
TIMI RISK SCORE 
 51 
 Age > 65 years 
 Presence of more than 3 risk factors for  CAD 
 Prior coronary stenosis   ≥ 50% 
 Presence of ST- segment deviation on admission ECG 
 More than 2 episodes of angina within past 24 hours 
 Prior use of aspirin in past 7 days 
 Elevated cardiac markers 
       One point is given when risk factor is present and zero points if 
absent ; with a total of 7 points being possible . Low risk patients (TIMI  
0 or 1) may be observed in a observation unit. If the patient remains  free 
of chest pain, has normal cardiac enzymes, a non invasive stress test 
should be performed for further risk stratification. Patients should be 
negative for cardiac enzymes prior to stress testing. Intermediate or high 
risk patients should be taken to the cardiac care unit and should undergo 
non invasive stress testing or coronary angiography based on their clinical 
course and risk profile. Patients with a TIMI score of 0/1 has an incidence 
of 4.7%  and those with a  score of 6/7 has 40.9% ,of death, new or 
recurrent MI or recurrent ischemia  requiring revascularisation. It is 
essential to determine the prognosis of patients with  MI as it is a valuable 
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tool for the practitioners to assess the risks and benefits of potential 
therapies. 
THROMBOLYTIC AGENTS: 
FIRST GENERATION :  
Streptokinase 
          Urokinase 
SECOND GENERATION :  
Recombinant tissue plasminogen activator (r- t PA, alteplase, 
duteplase), anisoylated plasminogen streptokinase activator complex 
(APSAC, anistreplase) 
THIRD GENERATION :  
Vampire bat salivary plasminogen activator, 
          Reteplase  
TNK – Tpa 
Lanoteplase(n-PA) 
 Tenecteplase 
   Staphylokinase 
Recombinant glycosylated plasminogen activator 
 
THROMBOLYTICS DRUGS UNDER DEVELOPMENT:  
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Antibody targeting thrombolytic agents 
Polyethylene glycol coupled thrombolytic agents 
Mutants and variants of plasminogen activator 
Recombinant chimeric plasminogen activator 
 
STATUS OF STREPTOKINASE IN DEVELOPING NATIONS 
  Streptokinase is the most  widely used thrombolytic agent  in 
developing nations like India.
14
 Because the cost of t-PA is ten times 
higher when compared to streptokinase, the latter  continues to be the 
fibrinolytic of choice in many developing nations.
15  
It has been proved in 
various studies that
  
Streptokinase is as efficacious as other fibrin specific 
agents in decreasing mortality. 
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 THROMBOLYTIC THERAPY IN ACUTE MI  
• It has been proved beyond doubt that5 early thrombolysis reduces 
mortality by 20-50%. This is achieved by reperfusion of the ischaemic 
myocardium which leads to limitation of the infarct size by 15-30%. 
Thrombolytics lead to bleeding in 0.5% of the population, however in 
several large trials the risk of bleeding was similar in thrombolytic & 
placebo group. 
• The therapeutic goals in acute myocardial infarction(AMI) are to 
retard coagulation and platelet function, reopen the affected coronary 
artery and achieve the greatest possible degree of myocardial 
reperfusion in the shortest possible time
4
. Clinical approaches usually 
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include a variable combination of thrombolysis, angioplasty, 
anticoagulation, platelet inhibition   and adrenergic blockade.' 
As access to primary angioplasty is often limited, thrombolytic 
drugs are the most powerful agents currently available for reversing 
coronary arterial occlusion in the majority of patients. 
STREPTOKINASE: Streptokinase (STREPTASE) is a 47,000-dalton 
protein produced by b-hemolytic streptococci. It has no intrinsic 
enzymatic activity, but it forms a stable, noncovalent 1:1 complex with 
plasminogen. This produces a conformational change that exposes the 
active site on plasminogen that cleaves arginine 560 on free plasminogen 
to form free plasmin. 
• INDICATIONS FOR THROMBOLYSIS 
• Early presentations (3 hours or less from symptom onset and delay 
to invasive strategy) 
• Invasive strategy is not an option 
Catheterization laboratory occupied / Not available 
Vascular access difficulties 
Lack of access to a skilled PCI laboratory 
• Delay to invasive strategy 
• Prolonged transport  
• (Door to balloon) – (Door to Needle) time is grater than 1 hour  
• Medical contact to balloon or door to balloon time is greater than 
90 minutes. 
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 Absolute contraindications include: 
• Those with Haemorrhagic stroke or stroke of unknown origin at 
any time.  History of Ischaemic stroke in preceding 6 months. CNS 
trauma or neoplasms . Recent  history major trauma/surgery/head 
injury (within preceding 3 weeks).Gastrointestinal bleeding within 
the last month ,history of known bleeding disorder, aortic 
dissection and Non-compressible punctures (e.g. liver biopsy, 
lumbar puncture) 
 Relative contraindications are:  
• Transient ischaemic attack in preceding 6 months 
• Oral anticoagulant therapy  
• Pregnancy or within 1 week post-partum  
• Refractory hypertension (SBP >180 mmHg  and/or  
DBP >110mmHg)   
• Advanced liver disease  
• Infective endocarditis  
• Active peptic ulcer; and      
• Refractory resuscitation 
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COMPLICATIONS OF STREPTOKINASE:  
Skin rashes, fever, anaphylaxis  are the allergic manifestations that 
occur in 1–2% of patients following streptokinase use. However  
hypotension  is the most common complication  of streptokinase  that 
usually responds to volume expansion. Due to of  potential of developing 
antibodies, patients who were previously treated with streptokinase 
should not receive  an alternate fibrinolytic drug. 
 The  main aim of thrombolysis is  to establish flow in the infarct related 
artery  without delay
2
. Achievement of reperfusion within half an hour of 
MI  can abort myocardial infarction. Reperfusion within half an hour to 
two hours can damage the myocardial tissue to a greater extent, and 
thrombolytic therapy given within this time frame may reduce mortality 
to the extent of 48%. Four fibrinolytic agents which are approved for 
STEMI are streptokinase, alteplase (tPA), reteplase, and tenecteplase 
3
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USEFULNESS OF STREPTOKINASE IN MI  
The GISSI trial observations proved that earlier admission to 
coronary care unit and administration of streptokinase was associated 
with better chances of recovery. The study establishes the usefulness of 
streptokinase in MI. GISSI trial was succeded by numerous other  clinical 
trials that strongly supported the use of streptokinase  in  MI patients.  
Following this lot of studies focussed on the choice of thrombolytic agent 
in AMI. 22 Large multicenter trials like GUSTO, GISSI -2 and ISIS-3  
compared the efficacy of tissue plasminogen activator (t-PA)  with that of 
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streptokinase. GUSTO trial found that there was no significant difference 
in mortality rates at the end of 30 days. GISSI-2 trial also reported similar 
mortality rates at the end of 6 months for patients randomized to receive 
t-PA or streptokinase. In addition, ISIS-3 also confirmed the fact that 
there was no major differences in mortality rates in those treated with  
streptokinase or t-PA. 
EFFECTS OF STREPTOKINASE ON LV FUNCTION 
3
Intravenous streptokinase preserves left ventricular function in 
patients with acute myocardial infarction. This benefit includes 
favourable effects on the function of regions remote from the site of 
infarction. Thus intravenous streptokinase administered within 3 h after 
the onset of AMI preserves global left ventricular function in anterior 
AMI over a period of at least 7 months. Intravenous streptokinase 
improves regional myocardial function within the infarct zone as well as 
in remote areas. 
 SURVIVAL BENEFIT  
 
12
ISIS-2 trial  clearly establishes the fact that early survival advantage 
produced by fibrinolytic therapy in acute myocardial infarction lasts for 
many years after treatment . The  survival benefits of fibrinolytic therapy 
lasts  for at least 10 years after treatment. 
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• THROMBOLYTIC THERAPY IN ELDERLY PATIENTS WITH 
MI : 
   Advanced age is the most important risk factor predictive of 
mortality in AMI. Although thrombolytic therapy has increased since 
1990 s, it is still underused in elderly patients. In patients 65 – 74 years of 
age, thrombolytic therapy has the greatest margin of benefit in absolute 
risk reduction. Despite the increased risk of bleeding in patients older 
than 75 years, the absolute net benefit is striking, with 18 lives saved 
per1000 patients treated. To combat the risk of haemorrhage, direct 
percutaneous revascularisation procedure may be considered in this age 
group. 
• ADJUVANT PERCUTANEOUS TRANSLUMINAL 
CORONARY ANGIOPLASTY: 
Studies have shown that immediate PTCA, may be superior to 
streptokinase in terms of recurrent ischaemia, reinfarction, and stroke 
rates as well as in patients with cardiogenic shock. The 4% risk of 
intracerebral haemorrhage in elderly patients receiving thrombolytic 
therapy can be greatly reduced or eliminated with PTCA, and insertion of 
stent may be an added advantage of angioplasty. 
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Because the efficacy of angioplasty depends more on operator skill 
and availability of suitable facilities and support personnel than does 
thrombolytic therapy and because of the significant delay in starting the 
procedure, PTCA cannot replace conventional thrombolytic agents for 
most patients. it has been suggested, however that thrombolytics therapy 
should be given in reduced dosage, even in pre hospital setting, and 
followed by PTCA in the hospital.  
 PREDICTORS OF FAILED THROMBOLYSIS 
24
About 25-50% of patients fail to achieve successful reperfusion 
and these patients have poor prognosis. Since alternative modes of 
reperfusion are available, it is important to identify them. Late 
presentation is an important risk factor for failed thrombolysis in AMI. 
Persistence of chest pain,
 
hyperglycemia and non-resolution of reciprocal 
ST depression are significantly associated with failed thrombolysis. 
FUTURE CONSIDERATIONS OF THROMBOLYTICS  
Despite several randomised trials proving that early thrombolytic 
therapy in patients with AMI reduces the mortality rate by approximately 
30% and that reperfusion therapy provides better results when 
administered in the first 60 – 90 mins after symptom onset, the median 
time from symptom to thrombolytic therapy is 2.5 hours, and the door to 
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thrombolytic injection is still more than 50 mins. Measures to reduce this 
period will improve outcomes. Another approach to improving the results 
of thrombolysis, regardless of timing, is to inhibit clot stabilization and 
thereby promote thrombolytic potential.Blocking factor XIII-a mediated 
reactions in a controlled and selective manner that does not interfere with 
the primary clotting time may prevent a significant portion of the clot 
from progressing to the fully stabilised state. This may also enhance clot 
lysis. Another possible approach is monoclonal antibody directed against 
the thrombin cleaving site of factor XIII, which will prevent its activation 
by thrombin. Factor XIIIa catalysed covalent attachment of á2-plasmin 
inhibitor to fibrin contributes significantly to lytic resistance, and this 
may be blocked by an antibody against it. It has been shown to promote 
clot lysis both in vitro and in animal models.Such inhibitors of clot 
stabilisation may facilitate thrombolysis with much lower doses of 
plasminogen activators than are currently used with reduced risk of 
haemorrhage.  
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AIMS AND OBJECTIVES 
  
To estimate  whether Selvester QRS scoring  would reliably 
predict resolution of ST segment  in patients with first acute ST 
segment elevation myocardial infarction receiving fibrinolytic  
therapy with  the drug streptokinase. 
 
 
 
 
 
 
 
 
 
 64 
MATERIALS AND METHODS 
The study was conducted on 62 patients admitted in the intensive 
coronary care unit of Government Rajaji Hospital, Madurai. Approval 
from the hospital ethical committee was obtained. 
STUDY DESIGN: 
The study was a cohort study conducted for a period of one year 
from March 2012 to August 2012. 
Inclusion criteria: 
 Patients with first acute STEMI in the age group of 30-80 years 
presenting within 24 hours from symptom onset, eligible for 
reperfusion therapy (presenting within 12 hours of symptom onset or 
presenting thereafter with persistent symptoms) were included in the 
study. 
 The diagnosis of STEMI was based on ECG findings of ST segment 
elevation >1mm in atleast two contiguous leads in a patient presenting 
with typical history of angina and with elevated CPK MB. 
. 
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Exclusion criteria: 
1. Patients with  bundle branch block, paced rhythm, left fascicular 
block. 
2. Ecg signs of ventricular hypertrophy. 
3. Patients with cardiogenic shock. 
Blood samples were collected for estimation of CPK MB, fasting 
lipid  profile, complete hemogram, blood sugar, blood urea and 
creatinine. 
DEFINITION OF RISK FACTORS 
The presence of hypertension was defined as systolic BP > 140mm 
Hg and diastolic BP >90 mmHg. The presence of diabetes was defined as 
fasting  plasma glucose >126 mg/dl and two hour glucose > 200 mg/dl. 
Dyslipidemia was defined as LDL cholesterol >100 mg/dl, TGL>150 
mg/dl, HDL<40 mg/dl in men and <50 mg/dl in women. 
METHOD: 
All patients in the study received fibrinolytic therapy in the form of 
streptokinase by intravenous infusion, at a dose of 1,50,000 U over 30 – 
60 mins. 12 lead ECG was taken for all patients from which the following 
was estimated: 
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1. QRS score was calculated according to modified Selvester QRS 
scoring system which incorporated 37 criteria  all together generating 
29 points. Score of > 4 in STE1 was considered to indicate non 
resolution of ST segment. 
2. ST segment elevation was measured 20 ms after the J point. The 
height (in mm) of ST segment elevations was measured in leads I, avL 
and V1 through  V6 for anterior infarctions and in leads II,III, aVF, for 
inferior infarctions. The sum of all measured ST segment elevations 
was expressed as STE1. 
Resting ECG  was repeated for all patients 90 mins after the initiation 
of fibrinolytic therapy, and the sum of ST segment elevations were 
estimated   and described as STE2. 
3. The difference between ST elevation in the first(resting)  and  90 mins 
ECG was calculated  and  expressed  as the sum of ST segment 
resolution  (∑STR) . Patients were grouped into those with {∑STR ≥ 
50% of STE1} resolution group and those with {∑STR< 50% of 
STE1} non resolution group. 
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 WHOLE 
COHORT 
n = 62 
RESOLUTION 
GROUP 
n = 32 
NON 
RESOLUTION 
GROUP 
n =30 
 
p 
value 
AGE 56.23±14.2 50.75±11.82 62.07±14.26 0.001 
MALE 44(71%) 24(54.5%) 20(45.5%)  
0.47 FEMALE 18(29%) 8(44.4%) 10(55.6%) 
SMOKING 32(51.6%) 19(59.4%) 13(40.6%) 0.207 
ALCOHOL 31(50%) 19(61.3%) 12(38.7%) 0.127 
HYPERTENSION 26(41.9%) 13(50%) 13(50%) 0.829 
DIABETES 25(40.3%) 8(32%) 17(68%) 0.011 
CARDIAC 
FAILURE 
15(24.2%) 2(13.3%) 13(86.7%) 0.001 
ANT WALL MI 39(62.9%) 17(43.6%) 22(56.4%) 0.1 
INF WALL MI 23(37.1%) 15(65.2%) 8(34.8%) 0.1 
DYSLIPIDEMIA 40(64.5%) 19(47.5%) 21(52.5%) 0.38 
 
TABLE 1:  BASE LINE CHARACTERISTICS OF WHOLE 
STUDY COHORT AND THE TWO STUDY GROUPS WITH 
RESPECT TO ST SEGMENT RESOLUTION 
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TABLE 2: BASE LINE CHARACTERISTICS OF WHOLE STUDY 
COHORT AND THE TWO STUDY GROUPS   
WITH  RESPECT TO QRS SCORE. 
 WHOLE 
COHORT 
QRS <4 QRS>4 p value 
AGE 56.23±14.2 50.88±13.37 62.31±12.65 0.001 
SMOKING 32(51.6%) 19(59.4%) 13(40.6%) 0.316 
ALCOHOL 31(50%) 20(64.5%) 11(35.5%) 0.075 
HYPERTENSION 26(41.9%) 9(34.6%) 17(65.4%) 0.013 
DIABETES 25(40.3%) 7(28%) 18(72%) 0.001 
CARDIAC 
FAILURE 
15(24.2%) 4(26.7%) 11(73.3%) 0.018 
ANT WALL MI 39(62.9%) 20(51.3%) 11(48.7%) 0.69 
INF WALL MI 23(37.1%) 13(56.5%) 10(43.5%) 0.69 
DYSLIPIDEMIA 40(64.5%) 20(50%) 20 (50%) 0.49 
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TABLE 3: ELECTROCARDIOGRAPHIC DATA OF THE OVERALL 
COHORT AND THE TWO STUDY GROUPS  
 
 WHOLE 
COHORT 
n= 62 
RESOLUTION 
GROUP 
n=32 
NON 
RESOLUTION 
GROUP  n= 30 
p value 
QRS SCORE 4.81±3.23 2.94±1.44 6.8±3.45 0.0001 
STE 1 33.56±18.35 30.66±14.58 36.67±21.49 0.206 
∑ STR 14.89±9.76 20±9.78 9.43±6.20 0.001 
EJECTION 
FRACTION 
39.13±7.77 43.84±4.82 34.10±7.17 0.0001 
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TABLE :  4  
ELECTROCARDIOGRAPHIC DATA OF THE OVERALL COHORT 
AND THE TWO STUDY GROUPS   
 WHOLE 
COHORT 
N = 62 
QRS 
SCORE 
< 4 
QRS 
SCORE 
> 4 
 
p value 
STE 1 33.56±18.35 30.95±15.38 36.52±21.12 0.238 
∑STR 14.89±9.76 18.33±10.24 10.97±6.72 0.002 
EJECTION 
FRACTION 
39.13±7.77 42.8±5.06 34.93±8.25 0.001 
 
Statistical analysis: 
Analysis was performed with SPSS VERSION 17.0 statistical 
package. All continuous variables were presented as mean ±standard 
deviation if they were normally distributed. Differences in the normally 
distributed variables were assessed using the t-test and the paired t-test 
for dependent variable. Comparisons between the two individual groups 
were performed using the unpaired t-test (parametric). Pearson’s 
correlation coefficient test was performed to study the correlation 
between the QRS score and the ∑STR. All tests were two-sided and a 
probability value of p < 0.05 was considered statistically significant. 
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RESULTS: 
A total of 60 consecutive patients with first event of acute STEMI  
who received fibrinolytic therapy were enrolled in the study. The baseline 
characteristics of the whole cohort, and the two study groups, are 
represented in Table 1 (in relation to ST segment resolution) and Table 2   
(in relation to QRS score). The mean age of the whole cohort was 
56.23±14.2 with 44(71%)   being males and 18(29%) being females. As 
compared to the resolution group, patients in the non-resolution group 
were older (62.07±14.26 vs 50.75 ± 11.82 respectively, p < 0.05), and 
QRS score [Table 2] was high in older population  (62.31±12.65 vs 
50.88±13.37 respectively, p value of 0.001).Sex did not have any 
significance  to the ST segment resolution ( p value  0.42) and the QRS 
score. Smoking( p value 0.207,p value 0.316) and alcohol  (p value 
0.127,p value 0.075) did not have  significance in relation  to the ST 
segment resolution and QRS score respectively, whereas  when compared 
to resolution group, patients in the non resolution group were 
diabetics{17(68%) vs 8(32%) respectively p value0.011 } and QRS score 
was higher in diabetics { 18 (72%) vs 7 (28%) respectively, p value 
0.001}. Congestive cardiac failure was higher in the non resolution group  
13(86.7%) when compared to the  resolution group 2(13.3%), p value 
0.001, similarly QRS score was high in patients with CCF (73.3%)when 
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compared to non CCF patients(38.3%), with a statistical significance of 
0.018. Hypertension (p value 0.829) did not have significance with 
respect to ST segment resolution, however hypertension was prevalent in 
patients with QRS > 4, p value 0.013. Type of MI (anterior wall or 
inferior wall) and dyslipidemia did not achieve significance in relation to 
the ST segment resolution (pvalue 0.1, p value 0.382) and QRS score 
(0.49,0.69,)  respectively.   Table 3 shows the electrocardiographic data of 
the overall cohort as well as the two study groups, the mean QRS score 
was less in the  ST segment resolution group when compared to the ST 
segment  non-resolution group (2.94± 1.44 vs 6.8 ± 3.45) respectively, p< 
.0001).There was a  stastically significant negative association  between 
QRS score and ∑STR with a correlation coefficient r2  = 0.1044 as shown 
in fig 1. 
There was also a significant negative correlation between QRS 
score and ejection fraction with a p value of .001.[ Table 4].  
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Table – 5 EFFECT OF SMOKING ON QRS SCORE AND ST 
SEGMENT RESOLUTION 
 
 QRS <4 QRS>4 p VALUE 
SMOKER 59.40% 40.60% 0.316 
 NON SMOKER 46.70% 53.30% 
 
 
 
RESOLUTION NON 
RESOLUTION 
NON 
RESOLUTION p VALUE 
SMOKER 59.40% 40.60% 
0.207 NON SMOKER 43.30% 56.70% 
 
There is no significant association between smoking and QRS 
score and ST segment resolution. 
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Table - 6 
EFFECT OF ALCOHOL ON QRS SCORE AND ST SEGMENT 
RESOLUTION 
 QRS <4 QRS>4 p VALUE 
ALCOHOL 64.50% 35.50% 
0.075 
NONALCOHOLIC 41.90% 58.10% 
 
 RESOLUTION 
NON 
RESOLUTION p VALUE 
ALCOHOLIC 61.3% 38.7% 
0.127 
NON ALCOHOLIC 41.90% 58.10% 
 
There is no significant association between alcohol and QRS score 
and  ST  segment resolution. 
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Table - 7 
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Effect of hypertension on QRS score and ST segment resolution 
 
 QRS <4 QRS>4 p value 
Hypertensives 34.60% 65.40% 
0.013 Non 
hypertensives 66.70% 33.30% 
 
 RESOLUTION 
NON 
RESOLUTION 
p value 
Hypertensives 50% 50% 
0.829 
Non hypertensives 52.80% 47.20% 
 
There is a significant association between hypertension and QRS score (p 
value  0.013), however there is no significant association between 
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hypertension and ST segment resolution. 
34.60% 66.70%
65.40% 33.30%
0.00% 20.00% 40.00% 60.00% 80.00% 100.00% 120.00%
QRS <4
QRS>4
HT NON HT
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52.80%
50%
47.20%
44%
45%
46%
47%
48%
49%
50%
51%
52%
53%
RESOLUTION NON RESOLUTION
HT NOT HYPERTENSION
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Table – 8 
Effect of Diabetes on QRS score and ST segment resolution   
 
 QRS<4 QRS>4 p VALUE 
DIABETIC 28% 72% 
0.001 
NON DIABETIC  70.30% 29.70% 
 
 RESOLUTION 
NON 
RESOLUTION 
p 
VALUE 
DIABETIC 32% 68% 
0.011 
NON DIABETIC 64.90% 35.10% 
 
There is a significant association between diabetes and QRS score 
(p value 0.001) and ST segment resolution (p value 0.011) 
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Table - 9 
  EFFECT OF CCF ON QRS score and ST segment resolution 
 QRS < 4 QRS > 4 p VALUE 
CCF 26.70% 73.30% 
0.018 
NO CCF 61.70% 38.30% 
 
  
 RESOLUTION 
NON 
RESOLUTION 
p 
VALUE 
CCF 13.30% 86.70% 0.001 
NO CCF 63.80% 36.20%  
 
There is a significant association between CCF and QRS score (p 
value  0.018) and ST segment resolution ( p value 0.001). 
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Table - 10 
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Effect of type of MI and QRS SCORE and ST segment resolution 
TYPE OF 
MI QRS < 4 QRS > 4 p VALUE 
ANT WALL 51.30% 48.70% 
0.69 
INF WALL 56.50% 43.50% 
 
 
TYPE OF MI RESOLUTION 
NON 
RESOLUTION p VALUE 
ANT MI 43.60% 056.40% 0.1 
INF MI 65.20% 34.80%  
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There was no significant association between the type of MI (Anterior or 
inferior wall ) with QRS score and ST segment resolution. 
QRS <4
QRS>4
ANT WALL
INF WALL
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60.00%
ANT
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INF
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RESOLUTION
NON
RESOLUTION
ANT MI INF MI
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Table - 11 
Effect of Dyslipidemia on QRS score and ST segment resolution 
 
 QRS < 4 QRS > 4 p VALUE 
DYSLIPIDEMIA 50% 50% 
0.49 
NO DYSLIPIDEMIA 59.10% 40.90% 
 
 
 RESSOLUTION 
NON 
RESOLUTION 
p 
VALUE 
DYSLIPIDEMIA 47.50% 52.50% 
0.382 NO 
DYSLIPIDEMIA 59.10% 40.90% 
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There is no association between dyslipidemia and QRS score and ST 
segment resolution 
50%
59.10%
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40.90%
0%
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20%
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 NO DYSLIPIDEMIA
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40.90%
0.00% 50.00% 100.00%
RESOLUTION
NON RESOLUTION
NO DYSLIPIDEMIA NO DYSLIPIDEMIA
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DISCUSSION 
           Patients with AMI arrive at our hospital relatively rapidly due to its 
central location and most of the patients could obtain maximum benefit of 
thrombolytic therapy because streptokinase (SK) is provided by 
government free of cost. Varied modes of reperfusion therapy for 
Myocardial Infarction have been developed.   But till date the most 
relevant treatment options are:  Streptokinase (1.5 MU over 1 Hour) 
reteplase (2 boluses of 10 MU), and alteplase (tissue plasminogen 
activator, t-PA, 100 mg over 1.5 hour) and immediate angioplasty. When 
compared to angioplasty, streptokinase is cheap and easily available. We 
used SK due to cost effectiveness. Treatment of acute STEMI with 
thrombolytic therapy showed greater mortality reduction. Various clinical 
trials have proved beyond doubt that treatment with streptokinase reduces 
mortality and it is now well accepted as the mainstay of revascularisation 
options for patients with acute myocardial infarction.  
            The relability  of  ST segment  nonresolution  in predicting 
mortality has been  extensively studied in many thrombolytic trials,  
ultimately proving beyond doubt  that patients with acute MI who have  
ST segment non resolution  are at risk  of persistent infarct-related artery 
occlusion, larger infarct size , CCF and increased  risk of death .On the 
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other hand, it was established that complete  resolution of the ST segment 
resolution is a powerful tool for predicting  flow in the infarct-related 
artery  and preserved myocardial tissue perfusion. Selvester QRS scoring 
system was originally developed to predict ‘electrocardiographically’ the 
size of infarct in a well-established infarction; we sought to employ it (in 
a simplified form) in our study to quantify the QRS complexes during the 
early stage of an ongoing infarction process. In this way, we hypothesized 
that we could have a measure of ‘how advanced the infarction process is’. 
We adopted the ‘< 50%’ ST segment resolution as a cut-off level to 
predict failed reperfusion. The current study demonstrated that a 
‘simplified form’ of the Selvester QRS score can reliably identify patients 
with acute STEMI who would achieve successful ST segment resolution 
after receiving fibrinolytic therapy. In these patients, value of  > 4 of the 
simplified QRS score could best identify those who would have 
inadequate ST segment resolution after this therapy. The importance of 
this study is that it offers a chance at avoiding unnecessary thrombolysis 
in patients who present beyond the time window of benefit from 
fibrinolytic therapy (more than 12 h after symptom onset) who sometimes 
have persistent symptoms. In these patients, fibrinolytic therapy might 
still have a probable, though doubtful, role. Thus it seems appealing to 
identify those who are more likely to benefit from fibrinolysis in this 
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patient category. A simple evaluation of the width and amplitude of QRS 
complexes in the admission ECG recordings (and hence calculation of the 
QRS score) would help in this stratification. In this way, one can avoid 
giving fibrinolytic therapy to patients who are less likely to benefit from 
it and restrict it to only those who are more likely to benefit from it. The 
other major benefit of this study is that ‘silent’ acute myocardial 
infarction can be incidentally discovered in ECG recordings of patients 
presenting with symptoms other than chest pain, especially in diabetics, 
elderly and patients who develop infarction under general anaesthesia. In 
these patients, it is often really a tough task to delineate precisely the time 
of onset of infarction, and consequently   whether the patient still lies 
within the time window for thrombolysis. In this situation, estimation of 
the QRS score could reliably offer an opportunity to recognize patients 
who are more likely to benefit from fibrinolytic regimens. Furthermore, 
even among patients presenting within the time window of thrombolysis, 
some have unusually increased risk of bleeding (as in elderly patients). In 
these patients, finding a high QRS score (at or above the cut-off value of 
4) would be a compelling factor against giving a fibrinolytic regimen. 
Diabetics had a higher QRS score and non resolution of STsegment, for 
hyperglycemia predisposes to failed thrombolysis
24
. Unsurprisingly heart 
failure and left ventricular dysfunction was higher in the non ST segment 
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resolution group. Iwakura et al 
25
noted that patients with no reflow as 
evidenced by myocardial contrast echocardiography, had a significantly 
higher Killip class on hospital admission than those with evidence of 
reflow. Insufficient myocardial perfusion at tissue level would lead to loss 
of more contractile units, that would translate into poor contractile 
function and pump failure. 
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CONCLUSION 
 
1.  It was found that as age advances non resolution of ST 
segment is higher and also the QRS scores are high. 
2. ST segment non resolution and QRS scores were high in 
diabetics. 
3.  Sex, smoking, alcohol had no effect on ST segment resolution 
and QRS score. 
4. Although hypertension had no effect on the ST segment 
resolution, hypertensives (without LVH) had a higher QRS 
score. 
5. The type of MI and dyslipidemia did not correlate well with 
ST segment resolution and QRS score. 
6.  Patients with congestive heart failure and low ejection fraction  
were  significantly  associated with non resolution of ST 
segment and high QRS score. 
7.  There was a statistically significant negative correlation 
between QRS score and ∑STR.  
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Thus the Modified Selvester QRS score can reliably estimate 
the resolution of ST segment in patients with acute STEMI receiving 
fibrinolytic therapy. Using the cut-off mark  of > 4, the QRS scoring 
system can estimate  ST segment non resolution with a high 
sensitivity and an acceptable specificity. 
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PROFORMA – CASE 
Name  :      Age  : 
Sex  : 
Occupation : 
Presenting complaints: Chest pain -   Duration 
    Breathlessness 
    NYHA class 
    Other complaints 
Past History   : 
    Type 2 DM 
    Hypertension 
    CAD 
Personal History  :  Smoker / Alcoholic   
Family History of IHD : 
General Examination :  Pallor 
     Pedal edema 
HR    : 
BP  : 
CVS  ;  S3 Gallop 
    Basal Crepitations 
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Type of MI  : Anterior Wall 
    Extensive 
    Anterolateral 
    Anteroseptal 
    Inferior wall 
    With posterior wall and RVMI 
KILLIP CLASS    : 
Median Delay : 
Lab   : Hb 
    CPK 
    Lipid profile 
STE – 1 : 
STE -  2 : 
STR  : > 50% Resolution 
   < 50% Resolution 
QRS Score  : 
ECHO  : 
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Leads STE1 STE2 
I   
II   
III   
aVR   
aVL   
aVF   
V1   
V2   
V3   
V4   
V5   
V6   
 Total = Total = 
 
>50% Resolution  
<50% Resolution  
 100 
Lead 
Duration  
(msec) 
 Amplitude ratios  Max points  
I Q>30 (1) R/Q<1 (1) 2  
II Q>40 
Q>30 
(2) 
(1) 
  
2  
aVL Q>30 (1) R/Q<1 (1) 2  
aVF Q>50 
Q>40 
Q>30 
(3) 
(2) 
(1) 
R/Q<1 
 
R/Q<2 
(2) 
 
(1) 
5  
V1 Any Q 
R>50 
R>40 
(1) 
(2) 
(1) 
 
 
R/S>1 
 
 
(1) 
 
4 
 
V2 Any Q or R<20 
R>60 
R>50 
(1) 
(2) 
(1) 
R/S>1.5 (1) 
4  
V3 Any Q or R < 30 (1)   1  
V4 Q>20 (1) R/Q or R/S<0.5 
R/Q or R/S <1 
(2) 
(1) 
3  
V5 Q>30 (1) R/Q or R/S < 1 
R/Q or R/S < 2 
(2) 
(1) 
3  
V6 Q>30 (1) R/Q or R/S <1 
R/Q or R/S <3 
(2) 
(1) 
3  
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SC
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EF
  
1 50 M 4 NO S smoker S NO S S         2 4 244 S 52 21 S   2 37% 
2 51 M 6 NO NO smoker S NO NO S         1 6 102 S 21 6 S   3 35% 
3 34 M 1 NO NO smoker N 0 NO NO S         1 1 166 N 73 45   S 7 35% 
4 43 M 3 S S NO S NO NO       S   1 3 184 S 7 4   S 6 49% 
5 68 M 3 NO S smoker S NO NO         S 1 3 791 S 15 6 S   4 42% 
6 69 M 7 NO NO smoker N 0 NO NO S         1 7 138 S 13 13   S 10 45% 
7 65 F 12 NO S NO N 0 NO NO         S 1 12 321 S 11 8   S 7 32% 
8 62 F 10 NO NO NO N 0 S S         S 2 10 624 S 10 8   S 2 45% 
9 55 M 10 S S smoker S NO NO         S 1 10 534 N 9 3 S   5 50% 
10 30 M 1 NO NO smoker S NO NO         S 1 1 321 N 32 11 S   3 46% 
11 45 M 6 NO NO smoker S NO S     S     2 6 556 S 15 13   S 6 40% 
12 55 M 5 NO NO smoker N 0 NO S     S     2 4 123 N 16 5   S 3 34% 
13 44 M 12 S NO NO S NO S S         2 12 345 S 28 20   S 5 35% 
14 23 M 10 NO NO smoker S NO S S         2 10 221 N 15 11   S 3 42% 
15 50 F 4 NO NO NO N 0 S NO         S 1 4 341 N 18 7 S   2 46% 
16 80 F 8 S S NO N 0 S NO S         1 8 211 S 29 7 S   2 44% 
17 47 M 4 NO S smoker N 0 NO NO         S 1 4 113 N 14 6 S   5 37% 
18 56 F 12 S S NO N 0 S S     S     2 12 435 N 35 13 S   6 33% 
19 67 F 7 S S NO N 0 NO NO       S   1 7 245 S 46 16 S   3 42% 
20 53 F 16 NO S NO N 0 S NO S         1 16 340 S 34 30   S 7 25% 
21 46 M 2 S NO smoker S NO NO     S     I 2 667 S 32 12 S   2 50% 
22 68 F 14 NO S NO N 0 S NO     S     1 14 134 N 56 40   S 2 42% 
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23 78 M 8 S S smoker N 0 NO NO   S       1 8 430 S 32 25   S 6 34% 
24 45 M 12 NO NO smoker alcoholic NO NO     S     1 12 221 N 58 20 S   3 41% 
25 50 F 6 S S NO N 0 S NO         S 1 6 543 S 45 12 S   6 50% 
26 62 F 16 S NO NO N 0 S S         S 2 16 444 S 18 12   S 12 23% 
27 32 M 4 NO NO smoker N 0 NO NO       S   1 4 560 S 12 4 S   2 45% 
28 78 M 12 S S smoker alcoholic NO S   S       2 12 789 S 42 34   S 14 24% 
29 39 M 5 NO NO NO alcoholic NO NO       S   1 5 549 N 18 7 S   1 50% 
30 80 F 8 S S NO N 0 NO S S         2 8 967 S 67 54   S 12 28% 
31 76 M 10 S NO smoker alcoholic NO NO     S     1 10 328 S 65 54   S 10 23% 
32 49 M 5 NO NO smoker alcoholic NO NO S         1 5 654 N 43 16 S   3 43% 
33 36 M 3 NO NO smoker alcoholic NO NO         S 1 3 566 S 16 6 S   2 45% 
34 48 M 8 S NO smoker alcoholic NO NO S         1 8 454 N 49 36   S 3 38% 
35 67 M 12 S NO smoker N 0 NO NO       S   1 12 123 S 56 38   S 6 40% 
36 79 M 10 NO S smoker alcoholic NO S S         2 10 1020 S 68 56   S 14 32% 
37 52 M 9 NO S smoker alcoholic NO NO       S   1 9 898 N 18 7 S   6 45% 
38 60 M 4 S NO NO N 0 NO NO S         1 4 659 S 32 12 S   3 48% 
39 55 M 7 NO NO smoker N 0 NO NO         S 1 7 774 S 17 6 S   2 40% 
40 72 M 5 S S NO N 0 NO NO     S     1 5 899 S 56 23 S S 3 38% 
41 62 M 6 S NO NO alcoholic NO NO       S   1 6 909 S 19 12   S 6 34% 
42 44 M 7 NO NO NO alcoholic NO NO   S       1 7 600 S 45 12 S   1 50% 
43 38 F 4 NO NO NO N 0 S NO     S     1 4 453 S 24 10 S   2 36% 
44 76 M 8 S NO NO N 0 NO NO   S       1 8 967 N 68 56   S 9 29% 
45 54 M 16 NO NO smoker alcoholic NO NO       S   1 16 1233 S 21 6 S   3 46% 
46 62 M 5 S NO smoker alcoholic NO NO S         1 5 322 N 47 30   S 8 42% 
47 35 M 3 S hyperten smoker alcoholic NO NO         S 1 3 233 N 17 6 S   2 48% 
48 63 M 13 NO hyperten smoker alcoholic S S S         2 13 990 N 49 29   S 5 32% 
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49 58 M 8 NO NO smoker alcoholic NO NO     S     1 6 356 S 34 12 S   2 48% 
50 67 M 2 S NO NO N 0 NO NO       S   1 2 777 N 24 19   S 5 41% 
51 47 M 7 S NO smoker alcoholic NO NO S         1 7 1232 S 58 17 S   2 42% 
52 32 M 2 NO NO NO alcoholic NO NO         S 1 2 875 N 18 5 S   1 50% 
53 63 F 10 S S NO N 0 S S   S       2 10 645 S 24 15   S 7 32% 
54 80 M 5 S S NO N 0 S S S         2 5 1231 S 68 54   S 10 23% 
55 51 M 14 NO NO NO alcoholic NO NO     S     1 14 342 S 26 17   S 2 32% 
56 49 M 3 NO NO smoker alcoholic NO NO     S     1 3 454 N 38 12 S   3 44% 
57 69 F 6 NO S NO N 0 S NO       S   1 6 343 S 14 10   S 2 34% 
58 57 F 12 S S NO N 0 S NO S         1 12 876 S 43 15 S   3 45% 
59 61 F 9 NO S NO N 0 S NO   S       1 9 232 S 24 10 S   5 42% 
60 72 F 13 S S NO N 0 S S S         2 13 534 S 54 45   S 8 26% 
61 59 M 10 NO NO smoker alcoholic NO NO S         1 10 683 N 41 15 S   2 45% 
62 68 F 8 S NO NO N 0 S NO   S       1 8 673 S 32 24   S 7 32% 
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ABBREVIATIONS 
 
STEMI  - ST ELEVATION MYOCARDIA INFARCTION 
STE 1  - SUM OF ST SEGMENT ELEVATION IN THE FIRST ECG 
STE 2  - SUM OF ST SEGMENT ELEVATION IN THE 90 MINS ECG 
∑STR  - DIFFERENCE BETWEEN STE 1 AND STE 2 
FHS  - FRANINGHAM HEART STUDY 
SK   - STREPTOKINASE 
GUSTO - GLOBAL UTILIZATION OF STREPTOKINASE AND 
TISSUE PLASMINOGEN ACTIVATOR FOR OCCLUDED 
CORONARY ARTERIES 
IRIS - INTERNATIONAL STUDY OF INFARCT SURVIVAL 
 COLLABORATION GROUP 
T PA  - TISSUE PLASMINOGEN ACTIVATOR 
GISSI - GRUPPO ITALINOPER SO STUDIO DELLA  
  SOPRAVVIENZANCIL INFARCTO 
ACC/AHA - AMERICAN COLLEGE OF CARDIOLOGY / AMERICAN  
  HEART ASSOCIATION 
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